For a patient with a glycated hemoglobin (HbA1c) of 7.3% who is being started on metformin, should I have them check blood glucose levels?

Blood Glucose Monitoring Not Routinely Necessary for Metformin Monotherapy

For a patient with HbA1c 7.3% starting metformin monotherapy, routine self-monitoring of blood glucose (SMBG) is generally unnecessary. 1

Key Recommendation

The most recent 2024 ACP guideline explicitly states that "self-monitoring of blood glucose might be unnecessary in patients receiving metformin combined with either an SGLT-2 inhibitor or a GLP-1 agonist" 1. While this statement specifically addresses combination therapy, the underlying principle applies even more strongly to metformin monotherapy alone, since metformin carries virtually no hypoglycemia risk.

Clinical Rationale

Why SMBG Is Not Required

• Metformin does not cause hypoglycemia 2, 3. The primary indication for frequent SMBG is to detect and prevent hypoglycemia, which occurs with insulin and sulfonylureas but not with metformin
• HbA1c monitoring is sufficient for assessing glycemic control on metformin. Guidelines recommend checking HbA1c every 3 months to evaluate treatment response 3, 4
• Cost and burden considerations: SMBG adds patient burden and expense without clear benefit when hypoglycemia risk is absent 5

When SMBG May Be Considered

You should consider recommending SMBG in specific circumstances:

• If symptoms of hyperglycemia develop (polyuria, polydipsia, weight loss) - to assess severity 6
• During intercurrent illness (fever, infection, surgery) when glucose levels may become unstable 6
• If considering treatment intensification - occasional pre-meal glucose checks can help guide whether to add a second agent 7
• Patient preference - some patients find occasional monitoring helpful for understanding their disease and reinforcing lifestyle modifications 5

Monitoring Strategy

Instead of routine SMBG, follow this approach:

1. Check HbA1c in 3 months to assess metformin response 3, 4
2. Educate the patient about symptoms of hyperglycemia that would warrant checking glucose 6
3. Emphasize lifestyle modifications (diet, exercise, weight loss) which remain critical 2, 3
4. Consider vitamin B12 monitoring periodically, as long-term metformin use can cause deficiency 3, 8

Treatment Targets and Next Steps

• Your patient's HbA1c of 7.3% is just above the target of 7-8% recommended for most adults 2, 1
• Metformin typically reduces HbA1c by 0.7-1.0% 3, which should bring this patient to goal
• If HbA1c remains ≥7% after 3 months on maximum tolerated metformin dose, add an SGLT-2 inhibitor or GLP-1 agonist based on comorbidities 1

Common Pitfall to Avoid

Do not reflexively order SMBG supplies for all diabetes patients. This outdated practice stems from the insulin era and adds unnecessary cost and complexity for patients on metformin monotherapy. Reserve SMBG for patients on medications that cause hypoglycemia (insulin, sulfonylureas) or those with unstable glycemic control requiring more frequent assessment.